[Corrections] Correction to Lancet Oncol 2017; 18: 1555–56

Bestvina CM and Vokes E. ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards. Lancet Oncol 2017; 18: 1555–56—In this Comment, the sixth sentence in the third paragraph should have read "Grade 3 or worse pulmonary toxicity occurred in 3% of patients treated with brigatinib." This correction has been made as of Nov 29, 2017, and the printed version is correct.

http://ift.tt/2kaQde8